TEYI PHARMACEUTICAL GROUP CO (SZSE:002728) Total Liabilities : ¥448.9 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is TEYI PHARMACEUTICAL GROUP CO Total Liabilities?

TEYI PHARMACEUTICAL GROUP CO's Total Liabilities for the quarter that ended in Mar. 2024 was ¥448.9 Mil.

TEYI PHARMACEUTICAL GROUP CO's quarterly Total Liabilities declined from Sep. 2023 (¥736.97 Mil) to Dec. 2023 (¥501.96 Mil) and declined from Dec. 2023 (¥501.96 Mil) to Mar. 2024 (¥448.94 Mil).

TEYI PHARMACEUTICAL GROUP CO's annual Total Liabilities increased from Dec. 2021 (¥804.51 Mil) to Dec. 2022 (¥1,142.47 Mil) but then declined from Dec. 2022 (¥1,142.47 Mil) to Dec. 2023 (¥501.96 Mil).

TEYI PHARMACEUTICAL GROUP CO Total Liabilities Historical Data

The historical data trend for TEYI PHARMACEUTICAL GROUP CO's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TEYI PHARMACEUTICAL GROUP CO Total Liabilities Chart

TEYI PHARMACEUTICAL GROUP CO Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

1,103.77

1,175.68

804.51

1,142.47

501.96

TEYI PHARMACEUTICAL GROUP CO Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															989.72	752.18	736.97	501.96	448.94

TEYI PHARMACEUTICAL GROUP CO Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

TEYI PHARMACEUTICAL GROUP CO's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	465.765	+	(0	+	36.19
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	502.0

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	2512.637	-	2010.682
	=	502.0

TEYI PHARMACEUTICAL GROUP CO's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	413.579	+	(0	+	35.362
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	448.9

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	2469.349	-	2020.408
	=	448.9

TEYI PHARMACEUTICAL GROUP CO Total Liabilities Related Terms

Thank you for viewing the detailed overview of TEYI PHARMACEUTICAL GROUP CO's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

TEYI PHARMACEUTICAL GROUP CO (SZSE:002728) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TEYI PHARMACEUTICAL GROUP CO LTD (SZSE:002728) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

Industrial Park pit, Guangdong Province, North, Taishan, CHN

Website

http://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO LTD is a pharmaceutical company. It engages in the research and development, production, and sale of proprietary Chinese medicines, and chemical drugs and raw materials in China. The main pharmaceutical preparation products cover a cough and phlegm, kidney, anti-infection, cardiovascular and digestive system. The main preparation products include Zhikebao Tablet, Jinqi Shenqi Tablet, Pharyngitis Tablet, and Erythromycin Enteric-coated Tablets.

Executives

Zhang Yong Zhao	Executives
Chen Xi Liang	Directors, Directors, and Executives
Xu Shao Hua	Securities Affairs Representative
Xu Wei Gao	Director
Xu Song Qing	Directors, executives
Liu Guang Tao	Executives
Du Yong Chun	Supervisors
Huang Yan Ling	Executives
Chen Guang Ting	Supervisors

TEYI PHARMACEUTICAL GROUP CO (SZSE:002728) Headlines

No Headlines